Literature DB >> 12951340

Ertapenem, the first of a new group of carbapenems.

Pramod M Shah1, Robin D Isaacs.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12951340     DOI： 10.1093/jac/dkg404

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  28 in total

1.  Efficacy and safety of ertapenem versus piperacillin-tazobactam for the treatment of intra-abdominal infections requiring surgical intervention.

Authors:  Arturo S Dela Pena; Walter Asperger; Ferdinand Köckerling; Raul Raz; Reinhold Kafka; Brian Warren; Malathi Shivaprakash; France Vrijens; Hilde Giezek; Mark J DiNubile; Christina Y Chan
Journal:  J Gastrointest Surg       Date:  2006-04       Impact factor: 3.452

2.  New drugs to treat skin and soft tissue infections.

Authors:  Gary E Stein
Journal:  Curr Infect Dis Rep       Date:  2007-09       Impact factor: 3.725

3.  Bowel colonization with resistant gram-negative bacilli after antimicrobial therapy of intra-abdominal infections: observations from two randomized comparative clinical trials of ertapenem therapy.

Authors:  M J Dinubile; I Friedland; C Y Chan; M R Motyl; H Giezek; M Shivaprakash; R A Weinstein; J P Quinn
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-07       Impact factor: 3.267

4.  Acquisition of resistant bowel flora during a double-blind randomized clinical trial of ertapenem versus piperacillin-tazobactam therapy for intraabdominal infections.

Authors:  Mark J DiNubile; Joseph W Chow; Vilas Satishchandran; Adam Polis; Mary R Motyl; Murray A Abramson; Hedy Teppler
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

5.  Ertapenem versus cefepime for initial empirical treatment of pneumonia acquired in skilled-care facilities or in hospitals outside the intensive care unit.

Authors:  S V Yakovlev; L S Stratchounski; G L Woods; B Adeyi; K A McCarroll; J A Ginanni; I R Friedland; C A Wood; M J DiNubile
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-10       Impact factor: 3.267

6.  Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal-weight, obese, and extremely obese adults.

Authors:  M Chen; A N Nafziger; G L Drusano; L Ma; J S Bertino
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

7.  Ertapenem pharmacokinetics and impact on intestinal microflora, in comparison to those of ceftriaxone, after multiple dosing in male and female volunteers.

Authors:  Mathias W R Pletz; Mareike Rau; Juergen Bulitta; Andres De Roux; Olaf Burkhardt; Guido Kruse; Michael Kurowski; Carl E Nord; Hartmut Lode
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

8.  Introduction of ertapenem into a hospital formulary: effect on antimicrobial usage and improved in vitro susceptibility of Pseudomonas aeruginosa.

Authors:  Ellie J C Goldstein; Diane M Citron; Victoria Peraino; Tanya Elgourt; Anne R Meibohm; Shuang Lu
Journal:  Antimicrob Agents Chemother       Date:  2009-09-28       Impact factor: 5.191

9.  Ertapenem resistance among extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae isolates.

Authors:  Azita Leavitt; Inna Chmelnitsky; Raul Colodner; Itzhak Ofek; Yehuda Carmeli; Shiri Navon-Venezia
Journal:  J Clin Microbiol       Date:  2009-02-11       Impact factor: 5.948

Review 10.  Comparative review of the carbapenems.

Authors:  George G Zhanel; Ryan Wiebe; Leanne Dilay; Kristjan Thomson; Ethan Rubinstein; Daryl J Hoban; Ayman M Noreddin; James A Karlowsky
Journal:  Drugs       Date:  2007       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.